Lian Liu, Song Li, Zimin Liu, Yanguo Liu, Kainan Li, Lei Cong, Fangli Cao, Aina Liu, Haiyan Liu, Ling Li, Linli Qu, Yi Zhai, Feng Wang, Dongmei Zhou, Ping Wang, Jisheng Li, Duanbo Shi. "Disitamab vedotin (RC48), tislelizumab, and S-1 as first-line therapy for HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Updated survival and exploratory biomarker results from the RCTS trial.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.4065